Abstract
Lymphomas are a heterogeneous group of clinical entities that develop from lymphocytes in different stages of maturity. They are the most frequent hematological neoplasm and the majority have their origin in B lymphocytes (80%). Hereditary, environmental, infectious, and immunological factors play a role in their etiopathogenesis. According to their clinical behavior, it is possible to distinguish between indolent lymphomas, such as follicular lymphoma, or aggressive lymphomas, such as Burkitt's lymphoma, among others. In general, T-cell lymphomas entail a worse prognosis, with shorter survival times. There are general prognostic indices, such as the IPI, which divide them into stages and help estimate survival whereas other, more specific indices have been created for certain subtypes of lymphoma, such as the FLIPI for follicular lymphoma or the MIPI for mantle cell lymphoma. Treatment differs widely from one type of lymphoma to another and based on its stage. It could vary from observation (watchful waiting) to intensive treatment, with intensification and transplantation of hematopoietic progenitor cells. To evaluate treatment response, the Lugano classification is used.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
